C-reactive Protein Testing Market

C-reactive Protein Testing Market (Test Type: Standard C-reactive Protein Test and High-sensitivity C-reactive Protein; Type of Assay: ELISA, Immunoturbidimetry, Immuno-chromatography, Immunofluorescence, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Global C-reactive Protein Testing Market Outlook 2031

  • The global industry was valued at US$ 3.1 Bn in 2022
  • It is projected to grow at a CAGR of 2.9% from 2023 to 2031 and reach more than US$ 4.0 Bn by the end of 2031

Analysts’ Viewpoint

The global C-reactive protein (CRP) testing market is expected to experience significant growth in the next few years. Prevalence of chronic diseases such as cardiovascular diseases, cancer, and autoimmune diseases is increasing across the world. Surge in demand for CRP testing for diagnosis and management of these diseases is likely propel market expansion. Furthermore, rise in usage of CRP testing in development of personalized medicine is projected to bolster market progress.

Advances in technology, such as development of high-sensitivity CRP assays and point-of-care CRP testing devices, are projected to offer lucrative opportunities to market players. Companies are focusing on development of standardized and accurate CRP tests to increase market share.

However, lack of standardization in CRP testing, which could lead to variability in test results and affect the accuracy of diagnoses, is anticipated to restrain the global C-reactive protein testing market.

C Reactive Protein Testing Market

C-reactive Protein Testing Market Introduction

C-reactive protein (CRP) testing is a medical diagnostic tool that measures the level of CRP, a protein produced by the liver in response to inflammation, in a patient's blood. CRP testing is widely used in the diagnosis and management of various conditions such as infections, autoimmune diseases, and cardiovascular diseases. It is particularly useful in detecting inflammation in the body, as elevated CRP levels are a marker of inflammation.

One of the primary applications of CRP testing is in the diagnosis and management of cardiovascular diseases. Elevated CRP levels are associated with an increased risk of heart attack and stroke, and CRP testing is often used to monitor patients with a history of cardiovascular disease. CRP testing is also used in the diagnosis and management of infectious diseases, such as pneumonia and sepsis, as well as autoimmune diseases, including rheumatoid arthritis and lupus.

The global market has witnessed significant growth in the past few years owing to an increase in the prevalence of inflammatory diseases and a rise in demand for high-quality diagnostic tools. The market is expected to be driven by a surge in the need for accurate and efficient diagnostic tools in the next few years.

Rise in Prevalence of Inflammatory Diseases

The rise in the prevalence of inflammatory diseases is likely to contribute to the growth of the global C-reactive protein testing market. CRP is an acute-phase protein that is produced by the liver in response to inflammation, infection, or tissue damage. Elevated levels of CRP in the blood could indicate the presence of inflammation in the body, which is associated with various diseases, including cardiovascular disease, rheumatoid arthritis, inflammatory bowel disease, and certain cancers. An increase in the incidence and prevalence of these diseases is projected to drive demand for CRP testing.

The surge in the adoption of point-of-care testing (POCT) for CRP, which enables rapid and convenient testing in primary care settings, is expected to propel market growth. Technological advancements in CRP testing methods, such as the development of high-sensitivity CRP assays, contribute to the growth of the market. These assays are more sensitive than traditional CRP tests and can detect lower levels of CRP in the blood, which could be useful in identifying patients who are at risk of developing inflammatory diseases or who may benefit from early intervention.

Overall, the rise in the prevalence of inflammatory diseases, the increase in the adoption of POCT for CRP, and technological advancements in CRP testing methods are likely to propel the market.

Increase in Demand for Point-of-Care Testing

POCT is a type of medical testing that is performed near the patient, rather than in a centralized laboratory, and provides results in real time. POCT for CRP enables rapid and convenient testing in primary care settings, emergency departments, and other point-of-care locations, which is especially beneficial for patients who require immediate diagnosis and treatment.

POCT for CRP could help reduce healthcare costs by eliminating the need for laboratory testing and reducing the time and resources required for diagnosis and treatment. This could also help improve patient outcomes by enabling early detection and intervention of inflammatory diseases. The COVID-19 pandemic has highlighted the importance of POCT in healthcare, as it enables rapid and accurate testing in remote or high-risk locations. Consequently, demand for POCT for various diseases, including CRP testing, has increased.

Overall, a surge in demand for POCT for CRP is expected to drive the global C-reactive protein testing market, as it provides a convenient and cost-effective alternative to laboratory testing, which could help improve patient outcomes and reduce healthcare costs.

High Adoption of Standard CRP Tests due to Wide Availability, Low Cost, and Accurate Results

In terms of test type, the standard C-reactive protein test segment held the largest global C-reactive protein testing market share in 2022. The standard C-reactive protein test is the most commonly used test for measuring CRP levels in the blood. CRP is a protein that is produced by the liver in response to inflammation in the body. The standard CRP test measures the level of CRP in the blood and is used to diagnose and monitor various conditions, such as infections, autoimmune disorders, and cardiovascular diseases. It is the most commonly used test in clinical practice, as it is widely available, relatively inexpensive, and provides accurate results in most cases.

The test is typically performed by drawing blood from a vein in the arm. The blood sample is then sent to a laboratory for analysis. Results are usually available within a few days. The standard CRP test measures CRP levels in the range of 1 to 10 milligrams per liter (mg/L). Higher levels of CRP in the blood indicate a greater level of inflammation in the body. However, the test is not specific to any particular disease or condition, so it is typically used in conjunction with other tests and clinical evaluations to diagnose and monitor various conditions.

Significant Usage of Immunoturbidimetry in Clinical Laboratories

Based on type of assay, the immunoturbidimetry segment dominated the global market in 2022. Immunoturbidimetry is a type of immunoassay used to measure the concentration of specific proteins or other molecules in a sample. The principle of immunoturbidimetry is based on the formation of a complex between the analyte of interest and a specific antibody, which leads to the formation of aggregates or complexes that scatter light, resulting in increased turbidity or opacity in the sample. This helps diagnose inflammatory conditions.

Immunoturbidimetry is a highly sensitive and specific method for measuring CRP levels and is widely used in clinical laboratories across the world. The technique involves mixing a sample of the patient's blood with a reagent that binds to CRP and then measuring the amount of light scattered by the resulting complex.

Increase in Prevalence and Incidence of Inflammatory Diseases

In terms of indication, the inflammatory diseases segment accounted for a significant global C-reactive protein testing market size in 2022. CRP test is commonly used to help diagnose and monitor inflammatory conditions such as rheumatoid arthritis, lupus, and inflammatory bowel disease. It can also be used to monitor the effectiveness of treatments for these conditions.

An increase in the prevalence and incidence of inflammatory diseases, such as inflammatory bowel disease (IBD), asthma, rheumatoid arthritis, and others, is anticipated to drive the inflammatory diseases segment during the forecast period.

The infectious diseases segment held the second-largest share of the global market in 2022. The rise in demand for CRP testing due to the rapid rise in the prevalence of infectious diseases globally and the increase in CRP testing rate for COVID-19 are propelling the segment.

Increase in Trend of Home Care Diagnostics & Testing Driving Independent Diagnostic Segment

Based on end-user, the independent diagnostic laboratories segment dominated the global market in 2022. The segment is projected to grow at a rapid pace during the forecast period due to an increase in the trend of home care diagnostics and testing. Independent diagnostic laboratories operate independently and can offer a wider range of services, such as direct-to-home testing, additional testing, and digital testing reports for the convenience of patients.

An increase in the number of independent diagnostic laboratories in the U.S. and Canada with advanced testing techniques and growing demand for direct-to-home testing services are anticipated to drive the independent diagnostic laboratories segment during the forecast period.

Regional Outlook

As per c-reactive protein testing market trends, North America accounted for the leading share of the global market in 2022. Point-of-care testing is becoming more popular in the region due to convenience and speed. POCT for CRP testing can provide rapid results, allowing for quicker diagnosis and treatment. Furthermore, advances in technology have made CRP testing more accurate, efficient, and affordable, which is expected to drive the market in North America during the forecast period.

The rise in the prevalence of inflammatory diseases, unhealthy lifestyles, and the development of new testing kits and solutions for early diagnosis of inflammatory conditions are anticipated to drive the market in North America during the forecast period. The strong presence of key players is another factor driving the market in the region.

The rise in the prevalence of chronic diseases, the increase in demand for early diagnosis & treatment, and the availability of advanced CRP testing technologies are likely to drive the CRP testing market in the Asia Pacific.

Analysis of Key Players in the Global C-reactive Protein Testing Market

Leading players in the global market have adopted strategies such as the expansion of product portfolios and merger & acquisition in order to increase market presence and share. Agilent Technologies, Inc., Laboratory Corporation of America Holdings, Thermo Fisher Scientific, Abbott Laboratories, F. Hoffmann-La Roche Ltd., Creative Diagnostics, DxGen Corp, CTK Biotech, Inc., Getein Biotech, Inc., Goldsite Diagnostics, Inc., OptiBio Co., Ltd., and Nanjing Vazyme Biotech Co., Ltd. are the prominent players in the global market.

Key Developments in Global C-reactive Protein Testing Market

  • In 2021, Randox Laboratories partnered with Qnostics to develop a new quality control material for CRP testing
  • In 2020, Beckman Coulter Life Sciences announced a collaboration with Thermo Fisher Scientific to develop and market a new high-sensitivity CRP assay
  • In May 2018, Abbott launched the Afinion 2 analyzer, the latest generation of the Afinion test system in the U.S. The Afinion 2 analyzer is now available in the U.S. and is already available with HbA1c, ACR, C-reactive protein (CRP), and the Lipid Panel in select markets outside of the U.S.

The C-reactive protein testing market report profiles key players based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Global C-reactive Protein Testing Market Snapshot

Attribute

Detail

Size in 2022

US$ 3.1 Bn

Forecast (Value) in 2031

US$ 4.0 Bn

Growth Rate (CAGR)

2.9%

Forecast Period

2023–2031

Historical Data Available for

2017–2021

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.

Competition Landscape

  • Market share analysis by company (2022)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Test Type
    • Standard C-reactive Protein Test
    • High-sensitivity C-reactive Protein (hs-CRP) Test
  • Type of Assay
    • ELISA
    • Immunoturbidimetry
    • Immuno-chromatography
    • Immunofluorescence
    • Others
  • Indication
    • Heart Diseases
    • Inflammatory Diseases
    • Infectious Diseases
    • Others
  • End-user
    • Hospital Associated Laboratories
    • Independent Diagnostic Laboratories
    • Others

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • South Africa
  • GCC Countries

Companies Profiled

  • Agilent Technologies, Inc.
  • Laboratory Corporation of America Holdings
  • Thermo Fisher Scientific
  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd.
  • Creative Diagnostics
  • DxGen Corp.
  • CTK Biotech, Inc.
  • Getein Biotech, Inc.
  • Goldsite Diagnostics, Inc.
  • OptiBio Co., Ltd.
  • Nanjing Vazyme Biotech Co., Ltd.

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

How big was the global C-reactive protein testing market in 2022?

The global industry was valued at US$ 3.1 Bn in 2022

How big will the C-reactive protein testing industry be in 2031?

It is projected to reach more than US$ 4.0 Bn by 2031

What will be the CAGR of the C-reactive protein testing business during the forecast period?

The CAGR is anticipated to be 2.9% from 2023 to 2031

Which are the prominent factors fueling demand for C-reactive protein testing?

Rise in prevalence of inflammatory diseases and increase in demand for point-of-care testing are driving the global market for C-reactive protein testing.

Which region will account for major share during the forecast period?

North America is projected to account for leading market share during the forecast period

Who are the prominent players in the global C-reactive protein Testing sector?

Agilent Technologies, Inc., Laboratory Corporation of America Holdings, Thermo Fisher Scientific, Abbott Laboratories, F. Hoffmann-La Roche Ltd., Creative Diagnostics, DxGen Corp, CTK Biotech, Inc., Getein Biotech, Inc., Goldsite Diagnostics, Inc., OptiBio Co., Ltd., and Nanjing Vazyme Biotech Co., Ltd. are the prominent players in the market.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global C-reactive Protein Testing Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Segment Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global C-reactive Protein Testing Market Analysis and Forecast, 2017–2031

    5. Key Insights

        5.1. Overview of C-reactive Protein Testing Market

        5.2. Key Product/ Brand Analysis

        5.3. Pipeline Analysis

        5.4. COVID-19 Pandemic Impact on Industry

    6. Global C-reactive Protein Testing Market Analysis and Forecast, by Test Type

        6.1. Introduction & Definition

        6.2. Key Findings/Developments

        6.3. Market Value Forecast, by Test Type, 2017–2031

            6.3.1. Standard C-reactive Protein Test

            6.3.2. High-sensitivity C-reactive Protein (hs-CRP) Test

        6.4. Market Attractiveness Analysis, by Test Type

    7. Global C-reactive Protein Testing Market Analysis and Forecast, by Type of Assay

        7.1. Introduction & Definition

        7.2. Key Findings/Developments

        7.3. Market Value Forecast, by Type of Assay, 2017–2031

            7.3.1. ELISA

            7.3.2. Immunoturbidimetry

            7.3.3. Immuno-chromatography

            7.3.4. Immunofluorescence

            7.3.5. Others

        7.4. Market Attractiveness Analysis, by Type of Assay

    8. Global C-reactive Protein Testing Market Analysis and Forecasts, by Indication

        8.1. Introduction & Definition

        8.2. Key Findings/Developments

        8.3. Market Value Forecast, by Indication, 2017–2031

            8.3.1. Heart Diseases

            8.3.2. Inflammatory Diseases

            8.3.3. Infectious Diseases

            8.3.4. Others

        8.4. Market Attractiveness Analysis, by Indication

    9. Global C-reactive Protein Testing Market Analysis and Forecast, by End-user

        9.1. Introduction & Definition

        9.2. Key Findings/Developments

        9.3. Market Value Forecast, by End-user, 2017–2031

            9.3.1. Hospital Associated Laboratories

            9.3.2. Independent Diagnostic Laboratories

            9.3.3. Others

        9.4. Market Attractiveness Analysis, by End-user

    10. Global C-reactive Protein Testing Market Analysis and Forecast, by Region

        10.1. Key Findings

        10.2. Market Value Forecast, by Region, 2017–2031

            10.2.1. North America

            10.2.2. Europe

            10.2.3. Asia Pacific

            10.2.4. Latin America

            10.2.5. Middle East & Africa

        10.3. Market Attractiveness Analysis, by Region

    11. North America C-reactive Protein Testing Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Test Type, 2017–2031

            11.2.1. Standard C-reactive Protein Test

            11.2.2. High-sensitivity C-reactive Protein (hs-CRP) Test

        11.3. Market Value Forecast, by Type of Assay, 2017–2031

            11.3.1. ELISA

            11.3.2. Immunoturbidimetry

            11.3.3. Immuno-chromatography

            11.3.4. Immunofluorescence

            11.3.5. Others

        11.4. Market Value Forecast, by Indication, 2017–2031

            11.4.1. Heart Diseases

            11.4.2. Inflammatory Diseases

            11.4.3. Infectious Diseases

            11.4.4. Others

        11.5. Market Value Forecast, by End-user, 2017–2031

            11.5.1. Hospital Associated Laboratories

            11.5.2. Independent Diagnostic Laboratories

            11.5.3. Others

        11.6. Market Value Forecast, by Country, 2017–2031

            11.6.1. U.S.

            11.6.2. Canada

        11.7. Market Attractiveness Analysis

            11.7.1. By Test Type

            11.7.2. By Type of Assay

            11.7.3. By Indication

            11.7.4. By End-user

            11.7.5. By Country

    12. Europe C-reactive Protein Testing Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Test Type, 2017–2031

            12.2.1. Standard C-reactive Protein Test

            12.2.2. High-sensitivity C-reactive Protein (hs-CRP) Test

        12.3. Market Value Forecast, by Type of Assay, 2017–2031

            12.3.1. ELISA

            12.3.2. Immunoturbidimetry

            12.3.3. Immuno-chromatography

            12.3.4. Immunofluorescence

            12.3.5. Others

        12.4. Market Value Forecast, by Indication, 2017–2031

            12.4.1. Heart Diseases

            12.4.2. Inflammatory Diseases

            12.4.3. Infectious Diseases

            12.4.4. Others

        12.5. Market Value Forecast, by End-user, 2017–2031

            12.5.1. Hospital Associated Laboratories

            12.5.2. Independent Diagnostic Laboratories

            12.5.3. Others

        12.6. Market Value Forecast, by Country/Sub-region, 2017–2031

            12.6.1. Germany

            12.6.2. U.K.

            12.6.3. France

            12.6.4. Italy

            12.6.5. Spain

            12.6.6. Rest of Europe

        12.7. Market Attractiveness Analysis

            12.7.1. By Test Type

            12.7.2. By Type of Assay

            12.7.3. By Indication

            12.7.4. By End-user

            12.7.5. By Country/Sub-region

    13. Asia Pacific C-reactive Protein Testing Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Test Type, 2017–2031

            13.2.1. Standard C-reactive Protein Test

            13.2.2. High-sensitivity C-reactive Protein (hs-CRP) Test

        13.3. Market Value Forecast, by Type of Assay, 2017–2031

            13.3.1. ELISA

            13.3.2. Immunoturbidimetry

            13.3.3. Immuno-chromatography

            13.3.4. Immunofluorescence

            13.3.5. Others

        13.4. Market Value Forecast, by Indication, 2017–2031

            13.4.1. Heart Diseases

            13.4.2. Inflammatory Diseases

            13.4.3. Infectious Diseases

            13.4.4. Others

        13.5. Market Value Forecast, by End-user, 2017–2031

            13.5.1. Hospital Associated Laboratories

            13.5.2. Independent Diagnostic Laboratories

            13.5.3. Others

        13.6. Market Value Forecast, by Country/Sub-region, 2017–2031

            13.6.1. China

            13.6.2. Japan

            13.6.3. India

            13.6.4. Australia & New Zealand

            13.6.5. Rest of Asia Pacific

        13.7. Market Attractiveness Analysis

            13.7.1. By Test Type

            13.7.2. By Type of Assay

            13.7.3. By Indication

            13.7.4. By End-user

            13.7.5. By Country/Sub-region

    14. Latin America C-reactive Protein Testing Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast, by Test Type, 2017–2031

            14.2.1. Standard C-reactive Protein Test

            14.2.2. High-sensitivity C-reactive Protein (hs-CRP) Test

        14.3. Market Value Forecast, by Type of Assay, 2017–2031

            14.3.1. ELISA

            14.3.2. Immunoturbidimetry

            14.3.3. Immuno-chromatography

            14.3.4. Immunofluorescence

            14.3.5. Others

        14.4. Market Value Forecast, by Indication, 2017–2031

            14.4.1. Heart Diseases

            14.4.2. Inflammatory Diseases

            14.4.3. Infectious Diseases

            14.4.4. Others

        14.5. Market Value Forecast, by End-user, 2017–2031

            14.5.1. Hospital Associated Laboratories

            14.5.2. Independent Diagnostic Laboratories

            14.5.3. Others

        14.6. Market Value Forecast, by Country/Sub-region, 2017–2031

            14.6.1. Brazil

            14.6.2. Mexico

            14.6.3. Rest of Latin America

        14.7. Market Attractiveness Analysis

            14.7.1. By Test Type

            14.7.2. By Type of Assay

            14.7.3. By Indication

            14.7.4. By End-user

            14.7.5. By Country/Sub-region

    15. Middle East & Africa C-reactive Protein Testing Market Analysis and Forecast

        15.1. Introduction

            15.1.1. Key Findings

        15.2. Market Value Forecast, by Test Type, 2017–2031

            15.2.1. Standard C-reactive Protein Test

            15.2.2. High-sensitivity C-reactive Protein (hs-CRP) Test

        15.3. Market Value Forecast, by Type of Assay, 2017–2031

            15.3.1. ELISA

            15.3.2. Immunoturbidimetry

            15.3.3. Immuno-chromatography

            15.3.4. Immunofluorescence

            15.3.5. Others

        15.4. Market Value Forecast, by Indication, 2017–2031

            15.4.1. Heart Diseases

            15.4.2. Inflammatory Diseases

            15.4.3. Infectious Diseases

            15.4.4. Others

        15.5. Market Value Forecast, by End-user, 2017–2031

            15.5.1. Hospital Associated Laboratories

            15.5.2. Independent Diagnostic Laboratories

            15.5.3. Others

        15.6. Market Value Forecast, by Country/Sub-region, 2017–2031

            15.6.1. GCC Countries

            15.6.2. South Africa

            15.6.3. Rest of Middle East & Africa

        15.7. Market Attractiveness Analysis

            15.7.1. By Test Type

            15.7.2. By Type of Assay

            15.7.3. By Indication

            15.7.4. By End-user

            15.7.5. By Country/Sub-region

    16. Competition Landscape

        16.1. Market Player - Competition Matrix (by tier and size of companies)

        16.2. Market Share Analysis, by Company (2022)

        16.3. Company Profiles

            16.3.1. Agilent Technologies, Inc.

                16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.1.2. Product Portfolio

                16.3.1.3. Financial Overview

                16.3.1.4. SWOT Analysis

                16.3.1.5. Strategic Overview

            16.3.2. Laboratory Corporation of America Holdings

                16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.2.2. Product Portfolio

                16.3.2.3. Financial Overview

                16.3.2.4. SWOT Analysis

                16.3.2.5. Strategic Overview

            16.3.3. Thermo Fisher Scientific

                16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.3.2. Product Portfolio

                16.3.3.3. Financial Overview

                16.3.3.4. SWOT Analysis

                16.3.3.5. Strategic Overview

            16.3.4. Abbott Laboratories

                16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.4.2. Product Portfolio

                16.3.4.3. Financial Overview

                16.3.4.4. SWOT Analysis

                16.3.4.5. Strategic Overview

            16.3.5. F. Hoffmann-La Roche Ltd.

                16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.5.2. Product Portfolio

                16.3.5.3. Financial Overview

                16.3.5.4. SWOT Analysis

                16.3.5.5. Strategic Overview

            16.3.6. Creative Diagnostics

                16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.6.2. Product Portfolio

                16.3.6.3. Financial Overview

                16.3.6.4. SWOT Analysis

                16.3.6.5. Strategic Overview

            16.3.7. DxGen Corp

                16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.7.2. Product Portfolio

                16.3.7.3. Financial Overview

                16.3.7.4. SWOT Analysis

                16.3.7.5. Strategic Overview

            16.3.8. CTK Biotech, Inc.

                16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.8.2. Product Portfolio

                16.3.8.3. Financial Overview

                16.3.8.4. SWOT Analysis

                16.3.8.5. Strategic Overview

            16.3.9. Getein Biotech, Inc.

                16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.9.2. Product Portfolio

                16.3.9.3. Financial Overview

                16.3.9.4. SWOT Analysis

                16.3.9.5. Strategic Overview

            16.3.10. Goldsite Diagnostics, Inc.

                16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.10.2. Product Portfolio

                16.3.10.3. Financial Overview

                16.3.10.4. SWOT Analysis

                16.3.10.5. Strategic Overview

            16.3.11. OptiBio Co., Ltd.

                16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.11.2. Product Portfolio

                16.3.11.3. Financial Overview

                16.3.11.4. SWOT Analysis

                16.3.11.5. Strategic Overview

            16.3.12. Nanjing Vazyme Biotech Co., Ltd.

                16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.12.2. Product Portfolio

                16.3.12.3. Financial Overview

                16.3.12.4. SWOT Analysis

                16.3.12.5. Strategic Overview

    List of Tables

    Table 01: Global C-reactive Protein Testing Market Value (US$ Mn) Forecast, by Test Type, 2017–2031

    Table 02: Global C-reactive Protein Testing Market Value (US$ Mn) Forecast, by Type of Assay, 2017‒2031

    Table 03: Global C-reactive Protein Testing Market Value (US$ Mn) Forecast, by Indication, 2017–2031

    Table 04: Global C-reactive Protein Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 05: Global C-reactive Protein Testing Market Value (US$ Mn) Forecast, by Region, 2017–2031

    Table 06: North America C-reactive Protein Testing Market Value (US$ Mn) Forecast, by Country, 2017–2031

    Table 07: North America C-reactive Protein Testing Market Value (US$ Mn) Forecast, by Test Type, 2017–2031

    Table 08: North America C-reactive Protein Testing Market Value (US$ Mn) Forecast, by Type of Assay, 2017‒2031

    Table 09: North America C-reactive Protein Testing Market Value (US$ Mn) Forecast, by Indication, 2017–2031

    Table 10: North America C-reactive Protein Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 11: Europe C-reactive Protein Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 12: Europe C-reactive Protein Testing Market Value (US$ Mn) Forecast, by Test Type, 2017–2031

    Table 13: Europe C-reactive Protein Testing Market Value (US$ Mn) Forecast, by Type of Assay, 2017‒2031

    Table 14: Europe C-reactive Protein Testing Market Value (US$ Mn) Forecast, by Indication, 2017–2031

    Table 15: Europe C-reactive Protein Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 16: Asia Pacific C-reactive Protein Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 17: Asia Pacific C-reactive Protein Testing Market Value (US$ Mn) Forecast, by Test Type, 2017–2031

    Table 18: Asia Pacific C-reactive Protein Testing Market Value (US$ Mn) Forecast, by Type of Assay, 2017‒2031

    Table 19: Asia Pacific C-reactive Protein Testing Market Value (US$ Mn) Forecast, by Indication, 2017–2031

    Table 20: Asia Pacific C-reactive Protein Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 21: Latin America C-reactive Protein Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 22: Latin America C-reactive Protein Testing Market Value (US$ Mn) Forecast, by Test Type, 2017–2031

    Table 23: Latin America C-reactive Protein Testing Market Value (US$ Mn) Forecast, by Type of Assay, 2017‒2031

    Table 24: Latin America C-reactive Protein Testing Market Value (US$ Mn) Forecast, by Indication, 2017–2031

    Table 25: Latin America C-reactive Protein Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 26: Middle East & Africa C-reactive Protein Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 27: Middle East & Africa C-reactive Protein Testing Market Value (US$ Mn) Forecast, by Test Type, 2017–2031

    Table 28: Middle East & Africa C-reactive Protein Testing Market Value (US$ Mn) Forecast, by Type of Assay, 2017‒2031

    Table 29: Middle East & Africa C-reactive Protein Testing Market Value (US$ Mn) Forecast, by Indication, 2017–2031

    Table 30: Middle East & Africa C-reactive Protein Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    List of Figures

    Figure 01: Global C-reactive Protein Testing Market Value (US$ Mn) Forecast, 2017–2031

    Figure 02: Global C-reactive Protein Testing Market Value Share, by Test Type, 2022

    Figure 03: Global C-reactive Protein Testing Market Value Share, by Types of Assay, 2022

    Figure 04: Global C-reactive Protein Testing Market Value Share, by Indication, 2022

    Figure 05: Global C-reactive Protein Testing Market Value Share, by End-user, 2022

    Figure 06: Global C-reactive Protein Testing Market Value Share Analysis, by Test Type, 2022 and 2031

    Figure 07: Global C-reactive Protein Testing Market Attractiveness Analysis, by Test Type, 2023–2031

    Figure 08: Global C-reactive Protein Testing Market Revenue (US$ Mn), by Standard C-reactive Protein Test , 2017–2031

    Figure 09: Global C-reactive Protein Testing Market Revenue (US$ Mn), by High-sensitivity C-reactive Protein (hs-CRP) Test, 2017–2031

    Figure 10: Global C-reactive Protein Testing Market Value Share Analysis, by Type of Assay, 2022 and 2031

    Figure 11: Global C-reactive Protein Testing Market Attractiveness Analysis, by Type of Assay, 2023–2031

    Figure 12: Global C-reactive Protein Testing Market Value (US$ Mn), by ELISA, 2017‒2031

    Figure 13: Global C-reactive Protein Testing Market Value (US$ Mn), by Immunoturbidimetry, 2017‒2031

    Figure 14: Global C-reactive Protein Testing Market Value (US$ Mn), by Irreversible Immuno-chromatography, 2017‒2031

    Figure 15: Global C-reactive Protein Testing Market Value (US$ Mn), by Immunofluorescence, 2017‒2031

    Figure 16: Global C-reactive Protein Testing Market Value (US$ Mn), by Others, 2017‒2031

    Figure 17: Global C-reactive Protein Testing Market Value Share Analysis, by Indication, 2022 and 2031

    Figure 18: Global C-reactive Protein Testing Market Attractiveness Analysis, Indication, 2023–2031

    Figure 19: Global C-reactive Protein Testing Market Revenue (US$ Mn), by Heart Diseases, 2017–2031

    Figure 20: Global C-reactive Protein Testing Market Revenue (US$ Mn), by Inflammatory Diseases, 2017–2031

    Figure 21: Global C-reactive Protein Testing Market Revenue (US$ Mn), by Infectious Diseases, 2017–2031

    Figure 22: Global C-reactive Protein Testing Market Revenue (US$ Mn), by Others, 2017–2031

    Figure 23: Global C-reactive Protein Testing Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 24: Global C-reactive Protein Testing Market Attractiveness Analysis, by End-user, 2023–2031

    Figure 25: Global C-reactive Protein Testing Market Revenue (US$ Mn), by Hospital Associated Laboratories, 2017–2031

    Figure 26: Global C-reactive Protein Testing Market Revenue (US$ Mn), by Independent Diagnostic Laboratories, 2017–2031

    Figure 27: Global C-reactive Protein Testing Market Revenue (US$ Mn), by Others, 2017–2031

    Figure 28: Global C-reactive Protein Testing Market Value Share Analysis, by Region, 2022 and 2031

    Figure 29: Global C-reactive Protein Testing Market Attractiveness Analysis, by Region, 2023–2031

    Figure 30: North America C-reactive Protein Testing Market Value (US$ Mn) Forecast, 2017–2031

    Figure 31: North America C-reactive Protein Testing Market Value Share Analysis, by Country, 2022 and 2031

    Figure 32: North America C-reactive Protein Testing Market Attractiveness Analysis, by Country, 2023–2031

    Figure 33: North America C-reactive Protein Testing Market Value Share Analysis, by Test Type, 2022 and 2031

    Figure 34: North America C-reactive Protein Testing Market Attractiveness Analysis, by Test Type, 2023–2031

    Figure 35: North America C-reactive Protein Testing Market Value Share Analysis, by Type of Assay, 2022 and 2031

    Figure 36: North America C-reactive Protein Testing Market Attractiveness Analysis, by Type of Assay, 2023–2031

    Figure 37: North America C-reactive Protein Testing Market Value Share Analysis, by Indication, 2022 and 2031

    Figure 38: North America C-reactive Protein Testing Market Attractiveness Analysis, Indication, 2023–2031

    Figure 39: North America C-reactive Protein Testing Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 40: North America C-reactive Protein Testing Market Attractiveness Analysis, by End-user, 2023–2031

    Figure 41: Europe C-reactive Protein Testing Market Value (US$ Mn) Forecast, 2017–2031

    Figure 42: Europe C-reactive Protein Testing Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 43: Europe C-reactive Protein Testing Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 44: Europe C-reactive Protein Testing Market Value Share Analysis, by Test Type, 2022 and 2031

    Figure 45: Europe C-reactive Protein Testing Market Attractiveness Analysis, by Test Type, 2023–2031

    Figure 46: Europe C-reactive Protein Testing Market Value Share Analysis, by Type of Assay, 2022 and 2031

    Figure 47: Europe C-reactive Protein Testing Market Attractiveness Analysis, by Type of Assay, 2023–2031

    Figure 48: Europe C-reactive Protein Testing Market Value Share Analysis, by Indication, 2022 and 2031

    Figure 49: Europe C-reactive Protein Testing Market Attractiveness Analysis, Indication, 2023–2031

    Figure 50: Europe C-reactive Protein Testing Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 51: Europe C-reactive Protein Testing Market Attractiveness Analysis, by End-user, 2023–2031

    Figure 52: Asia Pacific C-reactive Protein Testing Market Value (US$ Mn) Forecast, 2017–2031

    Figure 53: Asia Pacific C-reactive Protein Testing Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 54: Asia Pacific C-reactive Protein Testing Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 55: Asia Pacific C-reactive Protein Testing Market Value Share Analysis, by Test Type, 2022 and 2031

    Figure 56: Asia Pacific C-reactive Protein Testing Market Attractiveness Analysis, by Test Type, 2023–2031

    Figure 57: Asia Pacific C-reactive Protein Testing Market Value Share Analysis, by Type of Assay, 2022 and 2031

    Figure 58: Asia Pacific C-reactive Protein Testing Market Attractiveness Analysis, by Type of Assay, 2023–2031

    Figure 59: Asia Pacific C-reactive Protein Testing Market Value Share Analysis, by Indication, 2022 and 2031

    Figure 60: Asia Pacific C-reactive Protein Testing Market Attractiveness Analysis, Indication, 2023–2031

    Figure 61: Asia Pacific C-reactive Protein Testing Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 62: Asia Pacific C-reactive Protein Testing Market Attractiveness Analysis, by End-user, 2023–2031

    Figure 63: Latin America C-reactive Protein Testing Market Value (US$ Mn) Forecast, 2017–2031

    Figure 64: Latin America C-reactive Protein Testing Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 65: Latin America C-reactive Protein Testing Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 66: Latin America C-reactive Protein Testing Market Value Share Analysis, by Test Type, 2022 and 2031

    Figure 67: Latin America C-reactive Protein Testing Market Attractiveness Analysis, by Test Type, 2023–2031

    Figure 68: Latin America C-reactive Protein Testing Market Value Share Analysis, by Type of Assay, 2022 and 2031

    Figure 69: Latin America C-reactive Protein Testing Market Attractiveness Analysis, by Type of Assay, 2023–2031

    Figure 70: Latin America C-reactive Protein Testing Market Value Share Analysis, by Indication, 2022 and 2031

    Figure 71: Latin America C-reactive Protein Testing Market Attractiveness Analysis, Indication, 2023–2031

    Figure 72: Latin America C-reactive Protein Testing Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 73: Latin America C-reactive Protein Testing Market Attractiveness Analysis, by End-user, 2023–2031

    Figure 74: Middle East & Africa C-reactive Protein Testing Market Value (US$ Mn) Forecast, 2017–2031

    Figure 75: Middle East & Africa C-reactive Protein Testing Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 76: Middle East & Africa C-reactive Protein Testing Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 77: Middle East & Africa C-reactive Protein Testing Market Value Share Analysis, by Test Type, 2022 and 2031

    Figure 78: Middle East & Africa C-reactive Protein Testing Market Attractiveness Analysis, by Test Type, 2023–2031

    Figure 79: Middle East & Africa C-reactive Protein Testing Market Value Share Analysis, by Type of Assay, 2022 and 2031

    Figure 80: Middle East & Africa C-reactive Protein Testing Market Attractiveness Analysis, by Type of Assay 2023–2031

    Figure 81: Middle East & Africa C-reactive Protein Testing Market Value Share Analysis, by Indication, 2022 and 2031

    Figure 82: Middle East & Africa C-reactive Protein Testing Market Attractiveness Analysis, by Indication, 2023–2031

    Figure 83: Middle East & Africa C-reactive Protein Testing Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 84: Middle East & Africa C-reactive Protein Testing Market Attractiveness Analysis, by End-user, 2023–2031

    Figure 85: Global C-reactive Protein Testing Market Share Analysis By Company (2022)

Copyright © Transparency Market Research, Inc. All Rights reserved